Home / ZLDPF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ZLDPF make money? Does ZLDPF have pricing power? What's the Earnings Whisper? Will ZLDPF profit more as the business scales? What is ZLDPF's management track record? Is ZLDPF's current price justified?

Zealand Pharma A/S

$46.38 -$25.83 (-35.77%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$46.38

Day Range

$46.38 - $46.38

Year Range

$35.93$83.12

Market Cap

3.28B

AVG Volume

785

Trailing/Forward PE

7.14/5.42

PEG ratio

-0.11

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

Other OTC

Revenue (DKK)

ZLDPF Revenue (DKK) by year
Period	Revenue (DKK)
2025	9.21B
2024	62.69M
2023	342.79M
2022	111.09M
2021	292.57M
2020	353.31M
2019	41.33M
2018	39.08M
2017	139.78M
2016	234.55M

Net Income (DKK)

ZLDPF Net Income (DKK) by year
Period	Net Income (DKK)
2025	6.46B
2024	-1.08B
2023	-703.74M
2022	-1.09B
2021	-1.02B
2020	-846.82M
2019	-571.54M
2018	577.78M
2017	-272.27M
2016	-148.89M

Operating Income (DKK)

ZLDPF Operating Income (DKK) by year
Period	Operating Income (DKK)
2025	6.96B
2024	-1.27B
2023	-572.24M
2022	-939.68M
2021	-1.05B
2020	-792.36M
2019	-587.94M
2018	653.35M
2017	-246.38M
2016	-115.83M

EBITDA (DKK)

ZLDPF EBITDA (DKK) by year
Period	EBITDA (DKK)
2025	6.95B
2024	-978.21M
2023	-545.13M
2022	-746.97M
2021	-968.6M
2020	-816.27M
2019	-580.21M
2018	652.05M
2017	-255.67M
2016	-96.01M

Cash Flows (DKK)

ZLDPF Cash Flows (DKK) by year
Period	Cash Flows (DKK)
2025	6.88B
2024	-943.96M
2023	-449.42M
2022	-953.92M
2021	-1.23B
2020	-713.76M
2019	-432.97M
2018	-464.44M
2017	-285.97M
2016	38.3M

EPS (DKK)

ZLDPF EPS (DKK) by year
Period	EPS (DKK)
2025	94.62
2024	-17.27
2023	-12.55
2022	-23.69
2021	-23.72
2020	-21.68
2019	-17.2
2018	18.83
2017	-10.1
2016	-6.39

Expenses (DKK)

ZLDPF Expenses (DKK) by year
Period	Expenses (DKK)
2025	1.64B
2024	1.16B
2023	798.5M
2022	982.5M
2021	1.25B
2020	1.12B
2019	652.82M
2018	520.25M
2017	379.36M
2016	323.25M

Cash & Debt (DKK)

ZLDPF Cash & Debt (DKK) by year
Period	Cash & Debt (DKK)
2025	15.07B
2024	8.23B
2023	1.63B
2022	1.18B
2021	1.43B
2020	1.16B
2019	1.38B
2018	1.16B
2017	663.83M
2016	323.33M

Debt ratios

ZLDPF Debt ratios by year
Period	Debt ratios
2025	-3.12
2024	2.42
2023	0.49
2022	0.24
2021	0.37
2020	1.04
2019	4.63
2018	-5.31

Margins

ZLDPF Margins by year
Period	Margins
2025	99.9%
2024	76.88%
2023	53.45%
2022	94.23%
2021	59.39%
2020	74.37%
2019	99%
2018	-361.54%
2017	89.53%
2016	86.6%

Return on Capital

ZLDPF Return on Capital by year
Period	Return on Capital
2025	43.63%
2024	-12.52%
2023	-44.18%
2022	-133.15%
2021	-109.74%
2020	-71.94%
2019	-45.99%
2018	51.76%
2017	-51.52%
2016	-53.52%

Shares Outstanding

ZLDPF Shares Outstanding by year
Period	Shares Outstanding
2025	70.61M
2024	62.69M
2023	58.38M
2022	49.81M
2021	43.19M
2020	40.56M
2019	33.8M
2018	30.69M
2017	27.85M
2016	24.31M

Book Value Per Share (DKK)

ZLDPF Book Value Per Share (DKK) by year
Period	Book Value Per Share (DKK)
2025	209.57
2024	137.45
2023	27.28
2022	16.38
2021	21.48
2020	29.02
2019	36.76
2018	36.37
2017	18.97
2016	11.44

Total Assets (DKK)

ZLDPF Total Assets (DKK) by year
Period	Total Assets (DKK)
2025	16.42B
2024	9.51B
2023	1.98B
2022	1.54B
2021	2.07B
2020	1.92B
2019	1.6B
2018	1.23B
2017	737.24M
2016	694.63M

PE Ratio

ZLDPF PE Ratio by year
Period	PE Ratio
Sep 26	3.29
Sep 26	3.38
Aug 26	3.51
Aug 26	3.57
Aug 26	3.76
Aug 26	3.61
Jul 26	3.33
Jul 26	3.27
Jul 26	3.21
Jul 26	3.24
Jul 26	3.39
Jun 26	3.08
Jun 26	3.19
Jun 26	3.16
Jun 26	3.53
May 26	3.42
May 26	3.54
May 26	3.44
May 26	3.71
May 26	3.3
Apr 26	3.31
Apr 26	3.57
Apr 26	3.18
Apr 26	3.09
Mar 26	3.1
Mar 26	2.84
Mar 26	2.88
Mar 26	2.76
Feb 26	3.87
Feb 26	4.12
Feb 26	4.32
Feb 26	4.35
Jan 26	4.56
Jan 26	4.6
Jan 26	4.52
Jan 26	4.54
Jan 26	4.94
Dec 25	5.18
Dec 25	5.04
Dec 25	5.3
Dec 25	5.42
Nov 25	5.66
Nov 25	5.71
Nov 25	5.48
Nov 25	4.59
Oct 25	5.42
Oct 25	4.9
Oct 25	4.86
Oct 25	5.27
Oct 25	5.31

Free Cash Flow Yield

ZLDPF Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	31.83%
Sep 26	30.96%
Aug 26	29.85%
Aug 26	29.35%
Aug 26	27.89%
Aug 26	29.06%
Jul 26	31.47%
Jul 26	32.07%
Jul 26	32.64%
Jul 26	32.31%
Jul 26	30.93%
Jun 26	34.58%
Jun 26	33.36%
Jun 26	33.72%
Jun 26	30.18%
May 26	31.18%
May 26	30.09%
May 26	30.98%
May 26	28.69%
May 26	32.25%
Apr 26	32.17%
Apr 26	29.86%
Apr 26	33.49%
Apr 26	34.45%
Mar 26	38.2%
Mar 26	41.65%
Mar 26	41.09%
Mar 26	42.9%
Feb 26	30.59%
Feb 26	28.77%
Feb 26	27.43%
Feb 26	27.21%
Jan 26	26%
Jan 26	25.76%
Jan 26	26.22%
Jan 26	26.07%
Jan 26	23.95%
Dec 25	21.76%
Dec 25	22.35%
Dec 25	21.24%
Dec 25	20.78%
Nov 25	19.89%
Nov 25	19.73%
Nov 25	20.57%
Nov 25	24.54%
Oct 25	20.76%
Oct 25	23%
Oct 25	23.18%
Oct 25	21.38%
Oct 25	21.22%
Sep 25	-3.84%
Sep 25	-3.79%
Sep 25	-3.96%
Sep 25	-3.81%
Aug 25	-3.95%
Aug 25	-4.47%
Aug 25	-4.74%
Aug 25	-5.4%
Aug 25	-5.11%
Jul 25	-4.48%
Jul 25	-4.85%
Jul 25	-4.73%
Jul 25	-4.74%
Jun 25	-4.22%
Jun 25	-3.93%
Jun 25	-3.33%
Jun 25	-3.24%
May 25	-3.25%
May 25	-3.68%
May 25	-3.62%
May 25	-3.53%
May 25	-3.03%
Apr 25	-3.52%
Apr 25	-3.54%
Apr 25	-3.67%
Apr 25	-3.6%
Mar 25	-2.16%
Mar 25	-1.97%
Mar 25	-1.96%
Mar 25	-2.14%
Feb 25	-1.61%
Feb 25	-1.47%
Feb 25	-1.53%
Feb 25	-1.55%
Jan 25	-1.55%
Jan 25	-1.46%
Jan 25	-1.57%
Jan 25	-1.59%
Jan 25	-1.61%
Dec 24	-1.16%
Dec 24	-1.19%
Dec 24	-1.07%
Dec 24	-1.14%
Nov 24	-1.17%
Nov 24	-1.17%
Nov 24	-1.19%
Nov 24	-1.01%
Nov 24	-1.03%
Oct 24	-1.02%
Oct 24	-1.07%

Price to Sales

ZLDPF Price to Sales by year
Period	Price to Sales
Sep 26	2.28
Sep 26	2.34
Aug 26	2.43
Aug 26	2.47
Aug 26	2.6
Aug 26	2.5
Jul 26	2.3
Jul 26	2.26
Jul 26	2.22
Jul 26	2.24
Jul 26	2.35
Jun 26	2.16
Jun 26	2.24
Jun 26	2.21
Jun 26	2.47
May 26	2.39
May 26	2.48
May 26	2.41
May 26	2.6
May 26	2.31
Apr 26	2.32
Apr 26	2.5
Apr 26	2.23
Apr 26	2.17
Mar 26	2.22
Mar 26	2.03
Mar 26	2.06
Mar 26	1.97
Feb 26	2.77
Feb 26	2.94
Feb 26	3.09
Feb 26	3.11
Jan 26	3.26
Jan 26	3.29
Jan 26	3.23
Jan 26	3.25
Jan 26	3.53
Dec 25	3.8
Dec 25	3.69
Dec 25	3.89
Dec 25	3.97
Nov 25	4.15
Nov 25	4.19
Nov 25	4.02
Nov 25	3.37
Oct 25	3.98
Oct 25	3.59
Oct 25	3.56
Oct 25	3.86
Oct 25	3.89
Sep 25	573.26
Sep 25	580.4
Sep 25	556.41
Sep 25	577.36
Aug 25	557.18
Aug 25	492.37
Aug 25	464.8
Aug 25	407.51
Aug 25	430.78
Jul 25	491.98
Jul 25	454.34
Jul 25	465.7
Jul 25	464.56
Jun 25	357.15
Jun 25	382.9
Jun 25	452.37
Jun 25	465.41
May 25	463.08
May 25	409.3
May 25	415.63
May 25	426.97
May 25	496.17
Apr 25	428.07
Apr 25	425.84
Apr 25	410.75
Apr 25	418.64
Mar 25	427.55
Mar 25	469.77
Mar 25	472.6
Mar 25	432.26
Feb 25	573.16
Feb 25	629.63
Feb 25	603.16
Feb 25	595.33
Jan 25	596.23
Jan 25	632.71
Jan 25	589.37
Jan 25	580.86
Jan 25	573.76
Dec 24	126.13
Dec 24	122.45
Dec 24	136.51
Dec 24	128.11
Nov 24	124.98
Nov 24	125.26
Nov 24	122.98
Nov 24	144.27
Nov 24	141.96
Oct 24	143.64
Oct 24	136.27

EV/EBITDA

ZLDPF EV/EBITDA by year
Period	EV/EBITDA
Sep 26	1.04
Sep 26	1.12
Aug 26	1.24
Aug 26	1.3
Aug 26	1.48
Aug 26	1.33
Jul 26	1.07
Jul 26	1.01
Jul 26	0.96
Jul 26	0.99
Jul 26	1.13
Jun 26	0.76
Jun 26	0.87
Jun 26	0.84
Jun 26	1.18
May 26	1.07
May 26	1.19
May 26	1.09
May 26	1.35
May 26	0.97
Apr 26	0.98
Apr 26	1.21
Apr 26	0.86
Apr 26	0.77
Mar 26	0.63
Mar 26	0.4
Mar 26	0.43
Mar 26	0.32
Feb 26	1.33
Feb 26	1.56
Feb 26	1.74
Feb 26	1.77
Jan 26	1.96
Jan 26	2
Jan 26	1.92
Jan 26	1.95
Jan 26	2.31
Dec 25	2.53
Dec 25	2.4
Dec 25	2.65
Dec 25	2.75
Nov 25	2.98
Nov 25	3.02
Nov 25	2.81
Nov 25	1.99
Oct 25	2.76
Oct 25	2.27
Oct 25	2.24
Oct 25	2.61
Oct 25	2.65

Price/Operating Cashflow

ZLDPF Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Sep 26	3.13
Sep 26	3.21
Aug 26	3.33
Aug 26	3.39
Aug 26	3.57
Aug 26	3.42
Jul 26	3.16
Jul 26	3.1
Jul 26	3.05
Jul 26	3.08
Jul 26	3.22
Jun 26	2.88
Jun 26	2.98
Jun 26	2.95
Jun 26	3.3
May 26	3.19
May 26	3.31
May 26	3.21
May 26	3.47
May 26	3.09
Apr 26	3.09
Apr 26	3.33
Apr 26	2.97
Apr 26	2.89
Mar 26	2.61
Mar 26	2.4
Mar 26	2.43
Mar 26	2.33
Feb 26	3.26
Feb 26	3.47
Feb 26	3.64
Feb 26	3.67
Jan 26	3.84
Jan 26	3.87
Jan 26	3.81
Jan 26	3.83
Jan 26	4.16
Dec 25	4.58
Dec 25	4.46
Dec 25	4.7
Dec 25	4.8
Nov 25	5.01
Nov 25	5.06
Nov 25	4.85
Nov 25	4.07
Oct 25	4.8
Oct 25	4.34
Oct 25	4.3
Oct 25	4.67
Oct 25	4.7

Price to Book

ZLDPF Price to Book by year
Period	Price to Book
Sep 26	1.45
Sep 26	1.49
Aug 26	1.55
Aug 26	1.58
Aug 26	1.66
Aug 26	1.59
Jul 26	1.47
Jul 26	1.44
Jul 26	1.42
Jul 26	1.43
Jul 26	1.5
Jun 26	1.34
Jun 26	1.39
Jun 26	1.38
Jun 26	1.54
May 26	1.49
May 26	1.54
May 26	1.5
May 26	1.62
May 26	1.44
Apr 26	1.44
Apr 26	1.56
Apr 26	1.39
Apr 26	1.35
Mar 26	1.34
Mar 26	1.23
Mar 26	1.24
Mar 26	1.19
Feb 26	1.67
Feb 26	1.78
Feb 26	1.86
Feb 26	1.88
Jan 26	1.97
Jan 26	1.98
Jan 26	1.95
Jan 26	1.96
Jan 26	2.13
Dec 25	2.22
Dec 25	2.16
Dec 25	2.27
Dec 25	2.32
Nov 25	2.42
Nov 25	2.44
Nov 25	2.34
Nov 25	1.96
Oct 25	2.32
Oct 25	2.1
Oct 25	2.08
Oct 25	2.25
Oct 25	2.27
Sep 25	3.84
Sep 25	3.89
Sep 25	3.73
Sep 25	3.87
Aug 25	3.73
Aug 25	3.3
Aug 25	3.12
Aug 25	2.73
Aug 25	2.89
Jul 25	3.3
Jul 25	3.05
Jul 25	3.12
Jul 25	3.11
Jun 25	2.6
Jun 25	2.79
Jun 25	3.29
Jun 25	3.39
May 25	3.37
May 25	2.98
May 25	3.02
May 25	3.11
May 25	3.61
Apr 25	3.11
Apr 25	3.1
Apr 25	2.99
Apr 25	3.05
Mar 25	3.7
Mar 25	4.07
Mar 25	4.09
Mar 25	3.74
Feb 25	4.96
Feb 25	5.45
Feb 25	5.22
Feb 25	5.15
Jan 25	5.16
Jan 25	5.48
Jan 25	5.1
Jan 25	5.03
Jan 25	4.97
Dec 24	4.94
Dec 24	4.8
Dec 24	5.35
Dec 24	5.02
Nov 24	4.89
Nov 24	4.91
Nov 24	4.82
Nov 24	5.65
Nov 24	5.56
Oct 24	5.63
Oct 24	5.34

No video analysis for this stock yet. Request one from our team.

News: ZLDPF

zacks.com · 13 Aug 2026

Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates

Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago.

cnbc.com · 19 Jun 2026

Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide

cnbc.com · 13 Jun 2026

Drugmakers race to find a place in the next wave of obesity drugs

Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.